Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 04:44
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
Nokia says will cut up to 14,000 jobs
MTN’s Fintech Unit Seeks More Investors After Mastercard Deal
Scientists believe close kilonova explosion could threaten all life on Earth
Scientists have solved a great mystery at the dawn of time itself
The Supreme Court Just Handed Google and Twitter a New Line of Defense
Three down: Phone network not working as users report no service and lost messages
NASA discover signs of water and carbon on asteroid sample
AI’s Rapid Spread Is Sparking More Fears Than Job Losses for Now